Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in biologic-naive active psoriatic arthritis
NCT01695239Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of ixekizumab in psoriatic arthritis (PsA), sponsored by Eli Lilly and Company. Started Dec 2012; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01695239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695239.